TY - JOUR
T1 - Rosuvastatin Slows Progression of Carotid Intima-Media Thickness
T2 - The METEOR-China Randomized Controlled Study
AU - Zheng, Huaguang
AU - Li, Hongwei
AU - Wang, Yilong
AU - Li, Zhanquan
AU - Hu, Bo
AU - Li, Xiaogang
AU - Fu, Lu
AU - Hu, Hongtao
AU - Nie, Zhiyu
AU - Zhao, Bilian
AU - Wei, Di
AU - Karlson, Björn W.
AU - Bots, Michiel L.
AU - Meng, Xiang Wen
AU - Chen, Yundai
AU - Wang, Yongjun
N1 - Funding Information:
Medical writing support, which was funded by AstraZeneca, was provided by Steven Tresker of Cactus Life Sciences (part of Cactus Communications). We acknowledge all the investigators and site staff involved in this study and the personnel of the Vascular Imaging Center in Utrecht and the Ward A. Riley Ultrasound Center in Wake Forest for their contribution in the training of the sonographers and the reading of the images.
Publisher Copyright:
© 2022 Lippincott Williams and Wilkins. All rights reserved.
PY - 2022/10
Y1 - 2022/10
N2 - Background: Atherosclerosis is the leading cause of cardiovascular disease worldwide, including in China. Primary prevention, through lipid-lowering, could avert development of atherosclerosis. Carotid intima-media thickness (CIMT) is a well-validated measure of atherosclerosis used in intervention studies as the primary outcome and alternative end point for cardiovascular disease events. Methods: This randomized, double-blind, placebo-controlled, multicenter, parallel-group study assessed the effects of rosuvastatin 20 mg/d compared with placebo on progression of CIMT over 104 weeks in Chinese people with subclinical atherosclerosis. The primary end point was the annualized rate of change in mean of the maximum CIMT measurements taken 7× over the study period from each of 12 carotid artery sites (near and far walls of the right and left common carotid artery, carotid bulb, and internal carotid artery). Secondary end points included CIMT changes at different artery sites and lipid-parameter changes. Safety was also assessed. Results: Participants were randomized (1:1) to receive rosuvastatin (n=272) or placebo (n=271). Baseline characteristics were well balanced between groups. The change in mean of the maximum CIMT of the 12 carotid sites was 0.0038 mm/y (95% CI, -0.0023-0.0100) for the rosuvastatin group versus 0.0142 mm/y (95% CI, 0.0080-0.0204) for the placebo group, with a difference of -0.0103 mm/y (95% CI, -0.0191 to -0.0016; P=0.020). For the CIMT secondary end points, the results were generally consistent with the primary end point. There were clinically relevant improvements in lipid parameters with rosuvastatin. We observed an adverse-event profile consistent with the known safety profile of rosuvastatin. Conclusions: Rosuvastatin 20 mg/d significantly reduced the progression of CIMT over 2 years in Chinese adults with subclinical atherosclerosis and was well tolerated. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02546323.
AB - Background: Atherosclerosis is the leading cause of cardiovascular disease worldwide, including in China. Primary prevention, through lipid-lowering, could avert development of atherosclerosis. Carotid intima-media thickness (CIMT) is a well-validated measure of atherosclerosis used in intervention studies as the primary outcome and alternative end point for cardiovascular disease events. Methods: This randomized, double-blind, placebo-controlled, multicenter, parallel-group study assessed the effects of rosuvastatin 20 mg/d compared with placebo on progression of CIMT over 104 weeks in Chinese people with subclinical atherosclerosis. The primary end point was the annualized rate of change in mean of the maximum CIMT measurements taken 7× over the study period from each of 12 carotid artery sites (near and far walls of the right and left common carotid artery, carotid bulb, and internal carotid artery). Secondary end points included CIMT changes at different artery sites and lipid-parameter changes. Safety was also assessed. Results: Participants were randomized (1:1) to receive rosuvastatin (n=272) or placebo (n=271). Baseline characteristics were well balanced between groups. The change in mean of the maximum CIMT of the 12 carotid sites was 0.0038 mm/y (95% CI, -0.0023-0.0100) for the rosuvastatin group versus 0.0142 mm/y (95% CI, 0.0080-0.0204) for the placebo group, with a difference of -0.0103 mm/y (95% CI, -0.0191 to -0.0016; P=0.020). For the CIMT secondary end points, the results were generally consistent with the primary end point. There were clinically relevant improvements in lipid parameters with rosuvastatin. We observed an adverse-event profile consistent with the known safety profile of rosuvastatin. Conclusions: Rosuvastatin 20 mg/d significantly reduced the progression of CIMT over 2 years in Chinese adults with subclinical atherosclerosis and was well tolerated. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02546323.
KW - Adult
KW - Atherosclerosis/diagnostic imaging
KW - Cardiovascular Diseases/drug therapy
KW - Carotid Arteries/diagnostic imaging
KW - Carotid Artery Diseases/diagnostic imaging
KW - Carotid Intima-Media Thickness
KW - Disease Progression
KW - Fluorobenzenes/pharmacology
KW - Humans
KW - Lipids/pharmacology
KW - Pyrimidines/pharmacology
KW - Rosuvastatin Calcium/pharmacology
KW - Sulfonamides/pharmacology
UR - http://www.scopus.com/inward/record.url?scp=85139298071&partnerID=8YFLogxK
U2 - 10.1161/STROKEAHA.120.031877
DO - 10.1161/STROKEAHA.120.031877
M3 - Article
C2 - 36017704
AN - SCOPUS:85139298071
SN - 0039-2499
VL - 53
SP - 3004
EP - 3013
JO - Stroke
JF - Stroke
IS - 10
ER -